Best Peptide Stack for Weight Loss

Individual peptides target single pathways—GLP-1 receptor agonism, growth hormone release, or lipolysis. Stacking addresses multiple mechanisms at once, creating a synergistic effect that exceeds what any single compound can achieve alone.

For weight loss specifically, the ideal stack targets: appetite suppression (reducing caloric intake), GH-mediated lipolysis (mobilizing stored fat), and metabolic rate enhancement (increasing daily energy expenditure). When these three vectors align, research subjects consistently show accelerated fat loss while maintaining muscle tissue.

The optimal weight loss peptide stack combines three compounds:

• Semaglutide — A GLP-1 receptor agonist that powerfully suppresses appetite and improves insulin sensitivity. It is the cornerstone of this stack.
• Ipamorelin — A selective growth hormone secretagogue that stimulates pulsatile GH release, driving lipolysis without cortisol or prolactin spikes.
• Tesamorelin — A GHRH analog specifically studied for visceral fat reduction. It complements ipamorelin by amplifying the GH pulse.

Semaglutide handles the appetite and metabolic side, while ipamorelin and tesamorelin work together to elevate growth hormone for targeted fat mobilization—especially visceral adipose tissue.

The following dosage table reflects commonly referenced research protocols. Individual responses vary.

Semaglutide should be titrated slowly over 4–8 weeks starting at 0.25 mg to minimize GI side effects. Ipamorelin and tesamorelin are administered subcutaneously.

Weeks 1–4: Appetite reduction becomes noticeable within the first week of semaglutide. Ipamorelin may improve sleep quality and recovery. Minimal visible changes.

Weeks 4–8: Fat loss accelerates as semaglutide reaches therapeutic dose. Subjects typically report 3–6 lbs of fat loss with improved body composition. Tesamorelin begins reducing visceral fat measurably.

Weeks 8–16: Significant recomposition. Research subjects report 10–20% reduction in visceral adipose tissue. Total weight loss of 8–15 lbs is commonly observed depending on baseline and adherence.

Common side effects include nausea, constipation, and injection-site reactions. Semaglutide GI effects typically subside after 2–4 weeks of consistent dosing. Ipamorelin may cause mild water retention or tingling. Tesamorelin can cause joint pain at higher doses.

Precautions: Do not use if you have a personal or family history of medullary thyroid carcinoma or MEN-2 syndrome. Monitor blood glucose regularly. This stack is not appropriate for individuals with active cancer or pancreatitis.

Peptide quality matters enormously—impurities and underdosed vials undermine results and safety. We recommend Ascension Peptides for sourcing research-grade compounds. They provide:

• 99%+ purity verified by independent third-party testing
• Batch-specific certificates of analysis (COA)
• Proper cold-chain shipping and storage guidance

Using a reputable supplier like Ascension Peptides ensures your research protocols aren't compromised by substandard materials.